22 December 2006
Combined spinal epidural analgesia for labor with and without 3 ml of 1.5% epidural lidocaine
Yvonne Lim, Alex T Sia, Kok Yuen Ho, Alvin TeoMed Sci Monit 2007; 13(1): CR9-13 :: ID: 470142
Abstract
Background: Lidocaine is used as a ‘test dose’ to detect misplacement of epidural catheters. When administered immediately after the initiation of a combined spinal epidural for labor analgesia, it was found to interfere with motor function. The authors hypothesized that an epidural test dose of 3 ml of 1.5% lidocaine injected immediately after the initiation of combined spinal epidural analgesia and followed by a continuous epidural infusion would prolong the duration of analgesia and decrease the incidence of breakthrough pain.
Material/Methods: Sixty nulliparous parturients were recruited for this randomized controlled trial. Combined spinal epidural analgesia was performed with intrathecal levobupivacaine 2.5 mg and fentanyl 25 μg. The
patients were randomized into three groups: group L receiving 3 ml of 1.5% epidural lidocaine, group S 3 ml of normal saline, and group C the control group receiving no test solution. An epidural infusion of 0.1% levobupivacaine and 2 μg of fentanyl/ml at 10 ml/hr was initiated immediately.
Their need for supplementary analgesia, duration of analgesia, sensory block, motor block, side-effects, and overall satisfaction were recorded.
Results: The breakthrough pain rate in all groups were similar. Their mean duration of analgesia (mean survival times) were not signifi cantly different. Group C had the lowest incidence of lower limb motor block. The satisfaction scores were signifi cantly highest in group L.
Conclusions: The administration of epidural lidocaine and saline immediately after intrathecal levobupivacaine 2.5 mg and fentanyl 25 μg did not reduce the incidence of breakthrough pain in combined spinal epidural labor.
Keywords: Analgesia, Obstetrical, Analgesia, Epidural, Anesthetics, Local - pharmacology, Injections, Spinal, Labor, Obstetric - drug effects, Lidocaine - pharmacology, Pain Measurement, Pregnancy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952